transmembrane protein 260Genealiases: C14orf101 · SHDRA
Q-omics provides the consensus-scored TMEM260 profile across patient tissues and cancer cell-line models. TMEM260 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TMEM260 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, TMEM260 RNA expression shows 21,323 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where TMEM260 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM260 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM260 survival associations across molecular data types. TMEM260 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM260 RNA expression–survival associations across cancer types. High TMEM260 expression shows unfavorable associations in ACC and UVM, but favorable associations in LUSC, KIRC, SCLC and UCEC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TMEM260 RNA expression.
This table summarizes TMEM260 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM260. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM260 shows lower tumor expression in KIRC and THCA and higher tumor expression in HNSC, BLCA, LIHC and LUSC. The HNSC box plot shows higher TMEM260 RNA expression in tumor versus normal tissue (log2 FC = +0.754, t-test p < 0.001).
This table shows molecular features associated with TMEM260 in patient tissues and cancer cell lines. In patient samples, TMEM260 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM260 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
